International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
cll ipi score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–1
  • Intermediate Risk2–3
  • High Risk4–6
  • Very High Risk7–10
Direct Clinical Answer

The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include tp53 status. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.

Clinical Indication

The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) is indicated for bedside clinical practice to support Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: The CLL-IPI predicts overall survival and has been validated for time to first treatment.

Formula & Variables:

Score = TP53 abnormal (4) + IGHV unmutated (2) + β2-microglobulin >3.5mg/L (2) + Advanced stage (1) + Age >65 years (1)

Input Parameters

NameTypeRequiredDescription
tp53_statusstringYesTP53 gene abnormalities including del(17p) and/or TP53 mutation
ighv_statusstringYesIGHV (immunoglobulin heavy chain variable) mutational status
beta2_microglobulinstringYesSerum β2-microglobulin concentration level(mg/L)
clinical_stagestringYesClinical stage based on Binet or Rai staging systems
agestringYesPatient age category(years)

Score Interpretation & Guidance

RangeStageDescription
0–1Low RiskScore 0-1 points
2–3Intermediate RiskScore 2-3 points
4–6High RiskScore 4-6 points
7–10Very High RiskScore 7-10 points

Evidence-Based References (EBM)

  • An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016 Jul;17(7):779-90. doi: 10.1016/S1470-2045(16)30029-8.DOI: 10.1016/S1470-2045(16)30029-8
  • Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 28;135(22):1859-1869. doi: 10.1182/blood.2019003453.DOI: 10.1182/blood.2019003453
  • Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016 Oct 13;128(15):2093-2095. doi: 10.1182/blood-2016-07-728261.DOI: 10.1182/blood-2016-07-728261

Related calculators